Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Journal of Psychopharmacology

Volumn 29, Issue 3, 2015, Pages 280-288

  Hendricks, Peter S ^a   Thorne, Christopher B ^a   Clark, C Brendan ^b   Coombs, David W ^a   Johnson, Matthew W ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hallucinogen; lysergic acid diethylamide; mental health; prevention; psilocybin; Psychedelic; suicide

Indexed keywords

ILLICIT DRUG; PSYCHEDELIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISTRESS SYNDROME; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK REDUCTION; SUICIDAL IDEATION; SUICIDE ATTEMPT; UNITED STATES; ADOLESCENT; EPIDEMIOLOGY; MENTAL HEALTH; MENTAL STRESS; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; SUICIDE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; HALLUCINOGENS; HEALTH SURVEYS; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; STRESS, PSYCHOLOGICAL; SUICIDAL IDEATION; SUICIDE; SUICIDE, ATTEMPTED; UNITED STATES; YOUNG ADULT;

EID: 84924734110     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114565653     Document Type: Article

References (61)

1. Diagnostic and statistical manual of mental health disorders. 1994 ) Diagnostic and statistical manual of mental health disorders. 4th ed.Washington, DC: American Psychiatric Association Washington, DC: American Psychiatric Association ; 1994 :
2. Baumeister D, Barnes G, Giaroli G, et al. Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol. 2014 ; 4: 156-169
3. Bhagwagar Z, Hinz R, Taylor M, et al. Increased 5-HT2A receptor binding in euthymic, medication-free patients recovered from depression: A positron emission study with [11C] MDL 100,907. Am J Psychiatry. 2006 ; 163: 1580-1587
4. Black C, Miller JM. Meta-analysis of cytokines and chemokines in suicidality: Distinguishing suicidal versus non-suicidal patients. Biol Psychiatry. in press 2014 ;:
5. Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal. 2012 ; 4: 543-555
6. Borges G, Walters EE, Kessler RC. Associations of substance use, abuse, and dependence with subsequent suicidal behavior. Am J Epidemiol. 2000 ; 151: 781-789
7. Britton PC, Conner KR. Suicide attempts within 12 months of treatment for substance use disorders. Suicide Life Threat Behav. 2010 ; 40: 14-21
8. Carballo JJ, Akamnonu CP, Oquendo MA. Neurobiology of suicidal behavior. An integration of biological and clinical findings. Arch Suicide Res. 2008 ; 12: 93-110
9. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012b ; 109: 2138-2143
10. Carhart-Harris RL, Leech R, Williams TM, et al. Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012a ; 200: 238-244
11. Carhart-Harris RL, Leech R, Hellyer PJ, et al. The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014 ; 8: 20
12. Substance abuse and suicide prevention: Evidence and implications - A white paper. Rockville, MD: Substance Abuse and Mental Health Services Administration ; 2008 :
13. Dwivedi Y. Brain-derived neurotrophic factor and suicide pathogenesis. Ann Med. 2010 ; 42: 87-96
14. Dwivedi Y, Rizavi HS, Conley RR, et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003 ; 60: 804-815
15. Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014 ; 202: 513-520
16. Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. J Psychopharmacol. in press ; 29: 57-68
17. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology. 2011 ; 218: 649-655
18. Griffiths RR, Richards WA, Johnson MW, et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008 ; 22: 621-632
19. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006 ; 187: 268-283
20. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011 ; 68: 71-78
21. Hawton K, van Heeringen K. Suicide. Lancet. 2009 ; 373: 1372-1381
22. Hendricks PS, Clark CB, Johnson MW, et al. Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. J Psychopharmacol. 2014 ; 28: 62-66
23. Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014 ; 28: 983-992
24. Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: Guidelines for safety. J Psychopharmacol. 2008 ; 22: 603-620
25. Kashdan TB, Rose P, Fincham FD. Curiosity and exploration: Facilitating positive subjective experiences and personal growth opportunities. J Pers Assess. 2004 ; 82: 291-305
26. Kelley K, Clark B, Brown V, et al. Good practice in the conduct and reporting of survey research. Int J Qual Health Care. 2003 ; 15: 261-266
27. Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002 ; 32: 959-976
28. Kessler RC, Green JG, Gruber MJ, et al. Screening for serious mental illness in the general population with the K6 screening scale: Results from the WHO World Mental Health (WMH) survey initiative. Int J Methods Psychiatr Res. 2010 ; 19: 4-22
29. Khan A, Chien CW, Burton NW. A new look at the construct validity of the K6 using Rasch analysis. Int J Methods Psychiatr Res. 2014 ; 23: 1-8
30. Kraehenmann R, Preller KH, Scheidegger M, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. in press 2014 ;:
31. Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol. 2012 ; 26: 994-1002
32. Krebs TS, Johansen PO. Psychedelics and mental health: A population study. PLoS One. 2013 ; 8: e63972
33. Lerner M, Lyvers M. Values and beliefs of psychedelic drug users: A cross-cultural study. J Psychoactive Drugs. 2006 ; 38: 143-147
34. Lyvers M, Meester M. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. J Psychoactive Drugs. 2012 ; 44: 410-417
35. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011 ; 25: 1453-1461
36. Meyer JH, McMain S, Kennedy SH, et al. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry. 2003 ; 160: 90-99
37. Móró L, Simon K, Bárd I, et al. Voice of the psychonauts: Coping, life purpose, and spirituality in psychedelic drug users. J Psychoactive Drugs. 2011 ; 43: 188-198
38. Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, et al. Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci. 2013 ; 33: 15171-15183
39. A prioritized research agenda for suicide prevention: An action plan to save lives. Maryland: National Institute of Mental Health and the Research Prioritization Task Force, Rockville ; 2014 :
40. Nichols DE. Hallucinogens. Pharmacol Ther. 2004 ; 101: 131-181
41. Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Rev Neurosci. 2013 ; 14: 577-585
42. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: A multicriteria decision analysis. Lancet. 2010 ; 376: 1558-1565
43. Nutt D, King LA, Saulsbury W, et al. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007 ; 369: 1047-1053
44. Rasic DT, Belik SL, Elias B, et al. Spirituality, religion and suicidal behavior in a nationally representative sample. J Affect Disord. 2009 ; 114: 32-40
45. Rasic D, Robinson JA, Bolton J, et al. Longitudinal relationships of religious worship attendance and spirituality with major depression, anxiety disorders, and suicidal ideation and attempts: Findings from the Baltimore epidemiologic catchment area study. J Psychiatr Res. 2011 ; 45: 848-854
46. Roseman L, Leech R, Feilding A, et al. The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front Hum Neurosci. 2014 ; 8: 204
47. Segal DL, Marty MA, Meyer WJ, et al. Personality, suicidal ideation, and reasons for living among older adults. J Gerontol B Psychol Sci Soc Sci. 2012 ; 67: 159-166
48. Shelton RC, Sanders-Bush E, Manier DH, et al. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience. 2009 ; 158: 1406-1415
49. Szabo A, Kovacs A, Frecska E, et al. Psychedelic N, N-dimethyltryptamine and 5-methoxy-N, N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One. 2014 ; 9: e106533
50. Tagliazucchi E, Carhart-Harris R, Leech R, et al. Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapp. 2014 ; 35: 5442-5456
51. National Survey on Drug Use and Health, 2008. Ann Arbor, MI: Inter-university Consortium for Political and Social Research ; 2009 :
52. National Survey on Drug Use and Health, 2009. Ann Arbor, MI: Inter-university Consortium for Political and Social Research ; 2010 :
53. National Survey on Drug Use and Health, 2010. Ann Arbor, MI: Inter-university Consortium for Political and Social Research ; 2011 :
54. National Survey on Drug Use and Health, 2011. Ann Arbor, MI: Inter-university Consortium for Political and Social Research ; 2012 :
55. National Survey on Drug Use and Health, 2012. Ann Arbor, MI: Inter-university Consortium for Political and Social Research ; 2013 :
56. Varnik P. Suicide in the world. Int J Environ Res Public Health. 2012 ; 9: 760-771
57. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Rev Neurosci. 2010 ; 11: 642-651
58. Weber SR, Pargament KI. The role of religion and spirituality in mental health. Curr Opin Psychiatry. 2014 ; 27: 358-363
59. Whitfield-Gabrieli S, Ford JM. Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol. 2012 ; 8: 49-76
60. Wilcox HC, Conner KR, Caine ED. Association of alcohol and drug use disorders and completed suicide: An empirical review of cohort studies. Drug Alcohol Depend. 2004 ; 76: S11 - S19
61. The World health report 2001: Mental health: New understanding, new hope. Geneva, Switzerland: World Health Organization ; 2001 :